Lars Fruergaard Jørgensen, Novo Nordisk CEO (Christopher Goodney/Bloomberg via Getty Images)

No­vo Nordisk drops two pro­grams as it plots We­govy come­back

Two No­vo Nordisk pro­grams in obe­si­ty and car­dio­vas­cu­lar dis­ease are on the chop­ping block, the com­pa­ny buried in its Q3 re­port, as CEO Lars Fruer­gaard Jør­gensen plots a come­back in obe­si­ty.

The chief ex­ec­u­tive is shut­ting down a Phase I obe­si­ty pro­gram dubbed LA-GDF15 and a PC­SK9 in­hibitor that just com­plet­ed a Phase II tri­al in pa­tients with or at risk of de­vel­op­ing ath­er­o­scle­rot­ic car­dio­vas­cu­lar dis­ease (AS­CVD) due to “port­fo­lio con­sid­er­a­tions,” he said in the Q3 re­port.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters